Furthermore, conjugating IRdye700 to pertuzumab and trastuzumab that targets human epidermal growth factor receptor 2 (Her2)-expressing cancer cells revealed antitumor effects after NIR light irradiation [25,34,35,36,37]. This evidence concerns the gene ERBB2 and cancer.